A successfully treated case of primary purulent pericarditis complicated by cardiac tamponade and pneumopericardium. 2021 57(Suppl):186–8.īeom JW, Ko Y, Boo KY, Lee JG, Choi JH, Joo SJ, et al. Spontaneous pneumopericardium and pneumomediastinum in twelve covid-19 patients. Juárez-Lloclla JP, León-Jiménez F, Urquiaga-Calderón J, Temoche-Nizama H, Bryce-Alberti M, Portmann-Baracco A, et al. Epicardial catheter ablation of ventricular tachycardia. Epicardial ablation of ventricular tachycardia: a review. 2022 May 23.Ĭardoso R, Aryana A, Singh SM, Tandri H, d’Avila A. Epicardial catheter ablation of idiopathic ventricular arrhythmias originating from uncommon epicardial sites. Ju W, Zhang J, Shi L, Gu K, Chu M, Chen H, et al. Outcomes of a combined vs non-combinedendo-epicardial ventricular tachycardia ablation strategy. Matos D, Adragão P, Pisani C, Hatanaka V, Freitas P, Costa F, et al. Ablation strategies for arrhythmogenic right ventricular cardiomyopathy: a systematic review and meta-analysis. Shen LS, Liu LM, Zheng LH, Hu F, Hu ZC, Liu SY, et al. 2019 aphrs expert consensus statement on three-dimensional mapping systems for tachycardia developed in collaboration with hrs, ehra, and lahrs. Kim YH, Chen SA, Ernst S, Guzman CE, Han S, Kalarus Z, et al. Ventricular tachycardia ablation: past, present, and future perspectives. Epicardial ablation of ventricular tachycardia. Nontraumatic tension pneumopericardium in nonventilated pediatric patients: a review. 2019 14(3):134–7.īonardi CM, Spadini S, Fazio PC, Galiazzo M, Voltan E, Coscini N, et al. Asymptomatic pneumopericardium with atrial fibrillation after pericardiocentesis: a case report. Epicardial ventricular tachycardia ablation a multicenter safety study. Sacher F, Roberts-Thomson K, Maury P, Tedrow U, Nault I, Steven D, et al. A new technique to perform epicardial mapping in the electrophysiology laboratory. Sosa E, Scanavacca M, d’Avila A, Pilleggi F. The occurrence of pneumopericardium during the procedure may not significantly affect the long-term prognosis of patients. However, if recognized early and managed properly, it is unlikely to progress to tension pneumopericardium. The incidence of pneumopericardium during epicardial ablation was relatively high. The Kaplan–Meier survival analysis showed that there was no statistically significant difference in the incidence of MACEs between the two groups ( p = 0.28). Postoperative follow-up with a median period of 411 days showed that the incidence rate of major adverse cardiovascular events (MACEs), including the composite endpoints of all-cause death, rehospitalization for heart failure, and tachyarrhythmia events, was 36.4% ( n = 8) in the pneumopericardium group and 35.5% ( n = 23) in the non-pneumopericardium group. None of the cases progressed to tension pneumopericardium. The blood pressure (BP) decreased significantly, with the mean BP dropping from 119.8/73.2 to 103.5/64.9 mmHg ( p < 0.001). Twenty-two cases had pneumopericardium, with an incidence rate of 25.6%, and 12 (54.55%) patients complained of dyspnea during the procedure with an average occurrence time of 5.4 ± 3.2 min after pericardiocentesis. ResultsĪ total of 86 VA patients were included in the study. The occurrence of major adverse cardiovascular events (MACEs) was evaluated 1 year after the operation. The incidence of pneumopericardium was investigated. Patients with VA who underwent epicardial catheter ablation under local anesthesia at West China Hospital of Sichuan University from August 2012 to January 2022 were enrolled in this study. The purpose of this study was to evaluate the clinical effects of pneumopericardium during epicardial ablation on patients with VA. Pneumopericardium is a rare complication of epicardial ablation after dry pericardiocentesis to treat ventricular arrhythmia (VA) its exact clinical effects on patients are still unclear.